Regeneron beats quarterly estimates on eczema drug demand; launches dividend program
Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema ...
GlobalData on MSN16h
Galderma enters fierce European atopic dermatitis market with Nemluvio approval
Nemluvio, which was also approved for prurigo nodularis, becomes Galderma’s first approved biologic in its dermatology ...
Reuters11d
Regeneron beats quarterly estimates on eczema drug demand; launches dividend program
Feb 4 (Reuters) - Regeneron Pharmaceuticals (REGN.O), opens new tab beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema treatment, Dupixent, and ...
Investing10d
Regeneron beats quarterly estimates on eczema drug demand; launches dividend program
(Reuters) - Regeneron (NASDAQ:REGN) Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema treatment, Dupixent, and announced a dividend and ...
The Lancet1d
Patient in her 70s with COPD and asthma improving significantly since using monoclonal antibody dupilumab
Lyn Iemma, aged 75 years at the time of writing, would not describe her life as dramatic. Born and raised in Perth, WA, Australia, this thriving but relaxed city is the place she has always called ...
Insider Monkey26d
9 Stocks on Jim Cramer’s Radar
doesn’t matter if their breakthrough drug Dupixent is indicated for seven gigantic illnesses, asthma, eczema, [and] nasal polyps. This company has never lost its ability to develop new medicines ...
pharmaphorum3d
Sanofi's Dupixent scores double COPD win in US, China
Dupixent is already approved in the US for a variety of indications, going back to eczema in 2017 (and most recently for the treatment of the rare skin condition prurigo nodularis), but its ...